Modelling the population-level benefits and cost-effectiveness of cell-based quadrivalent influenza vaccine for children and adolescents aged 6 months to 17 years in the US by Stephen I. Pelton, Joaquin F. Mould-Quevedo, Van Hung Nguyen

Get full text

Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France by Marc Paccalin, Gaëtan Gavazzi, Quentin Berkovitch, Henri Leleu, Romain Moreau, Emanuele Ciglia, Nansa Burlet, Joaquin F. Mould-Quevedo

Get full text

Editorial: Clinical, biological, and economic aspects of pediatric infections in Latin America by Juan Garduño-Espinosa, Fortino Solórzano-Santos, Guillermo Salinas-Escudero, Guadalupe Miranda-Novales, Joaquin F. Mould-Quevedo, Diana Avila-Montiel

Get full text

A Clinical and Economic Comparison of Cell-Based Versus Recombinant Influenza Vaccines in Adults 18–64 Years in the United States by Myron J. Levin, Neda Al Rawashdh, Liliane Mofor, Pablo Anaya, Richard M. Zur, Emily B. Kahn, Daniel Yu, Joaquin F. Mould-Quevedo

Get full text

The economic rationale for cell-based influenza vaccines in children and adults: A review of cost-effectiveness analyses by David Fisman, Norberto Giglio, Myron J. Levin, Van Hung Nguyen, Stephen I. Pelton, Maarten Postma, Jesús Ruiz-Aragón, Analia Urueña, Joaquin F. Mould-Quevedo

Get full text

Modelling the Relative Vaccine Efficacy of ARCT-154, a Self-Amplifying mRNA COVID-19 Vaccine, versus BNT162b2 Using Immunogenicity Data by Van Hung Nguyen, Pascal Crépey, Jean Marie Pivette, Ethan Settembre, Sankarasubramanian Rajaram, John Youhanna, Aimee Ferraro, Cheng Chang, Josephine van Boxmeer, Joaquin F. Mould-Quevedo

Get full text